HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Toshio Hirakawa Selected Research

Toshio Hirakawa Research Topics

Disease

13Neoplasms (Cancer)
12/2006 - 11/2002
11Ovarian Neoplasms (Ovarian Cancer)
07/2007 - 02/2002
6Hypersensitivity (Allergy)
05/2006 - 01/2004
4Carcinoma (Carcinomatosis)
07/2007 - 02/2002
3Edema (Dropsy)
08/2004 - 01/2004
2Hydatidiform Mole (Molar Pregnancy)
07/2010 - 12/2006
2Adenocarcinoma
10/2005 - 08/2004
2Hypotension (Low Blood Pressure)
07/2005 - 01/2004
2Breast Neoplasms (Breast Cancer)
07/2005 - 11/2002
2Uterine Cervical Neoplasms (Cancer of the Cervix)
06/2005 - 08/2004
2Neutropenia
09/2004 - 08/2004
1Triploidy
07/2010
1Hemorrhage
12/2006
1Uterine Neoplasms (Uterine Cancer)
12/2006
1Placenta Previa
12/2006
1Urticaria (Hives)
07/2005
1Flushing
07/2005
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
07/2005
1Obesity
07/2005
1Amenorrhea
12/2004
1Granulosa Cell Tumor
12/2004
1Dysgerminoma
11/2004
1Leukopenia
09/2004
1Acute Lung Injury
08/2004
1Pain (Aches)
08/2004
1Endometrial Neoplasms (Endometrial Cancer)
08/2004
1Neoplasm Metastasis (Metastasis)
03/2004
1Bronchial Spasm
01/2004
1Papillary Adenocarcinoma
12/2002
1Endometrioid Carcinoma
11/2002
1Endometriosis
11/2002
1Cysts
11/2002
1Clear Cell Adenocarcinoma
02/2002

Drug/Important Bio-Agent (IBA)

9Paclitaxel (Taxol)FDA LinkGeneric
07/2007 - 01/2004
4Histamine (Histamine Dihydrochloride)FDA Link
07/2005 - 01/2004
3Carboplatin (JM8)FDA LinkGeneric
07/2007 - 07/2005
3AntigensIBA
12/2006 - 06/2005
3Peptides (Polypeptides)IBA
05/2006 - 01/2004
3Cisplatin (Platino)FDA LinkGeneric
09/2004 - 11/2002
3Antineoplastic Agents (Antineoplastics)IBA
08/2004 - 01/2004
2DNA (Deoxyribonucleic Acid)IBA
07/2010 - 12/2006
2Biological ProductsIBA
12/2006 - 03/2004
2pemirolast (Alamast)FDA Link
05/2006 - 05/2004
2Anti-Allergic Agents (Antiallergic Agents)IBA
05/2006 - 05/2004
2Doxorubicin (Adriamycin)FDA LinkGeneric
09/2004 - 08/2004
2Substance PIBA
08/2004 - 07/2004
2Pharmaceutical PreparationsIBA
03/2004 - 11/2002
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
07/2003 - 02/2002
1Proteins (Proteins, Gene)FDA Link
07/2007
1Member 1 Subfamily B ATP Binding Cassette TransporterIBA
07/2007
1Biomarkers (Surrogate Marker)IBA
12/2006
1CalponinsIBA
09/2006
1Therapeutic UsesIBA
09/2006
1VimentinIBA
10/2005
1GlucocorticoidsIBA
07/2005
1Fas Ligand Protein (Fas Ligand)IBA
06/2005
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2005
1inhibin BIBA
12/2004
1Gonadotropin-Releasing Hormone (GnRH)FDA Link
12/2004
1Inhibins (Inhibin)IBA
12/2004
1isolated Follicle-stimulating hormone deficiencyIBA
12/2004
1beta CateninIBA
11/2004
1Cyclin D1IBA
11/2004
1IodineIBA
08/2004
1Ioxaglic Acid (Ioxaglate Meglumine)FDA Link
08/2004
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
08/2004
1Indicators and Reagents (Reagents)IBA
08/2004
1Epirubicin (Ellence)FDA LinkGeneric
08/2004
1AnthracyclinesIBA
08/2004
1pirarubicinIBA
08/2004
1Oxygen (Dioxygen)IBA
07/2004
11- (N- (2- methoxybenzyl)acetylamino)- 3- (1H- indol- 3- yl)- 2- (N- (2- (4- (piperidin- 1- yl)piperidin- 1- yl)acetyl)amino)propane (Lanepitant)IBA
07/2004
1NeuropeptidesIBA
05/2004
1Dexamethasone (Maxidex)FDA LinkGeneric
01/2004
1Thymidine PhosphorylaseIBA
07/2003
1Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
07/2003
1Interleukin-8 (Interleukin 8)IBA
07/2003
1Messenger RNA (mRNA)IBA
12/2002
1ATP-Binding Cassette Transporters (ABC Transporters)IBA
12/2002
1multidrug resistance-associated protein 1IBA
12/2002
1Adenosine Triphosphate (ATP)IBA
12/2002
1TamoxifenFDA LinkGeneric
11/2002
1DNA-Binding Proteins (DNA Binding Protein)IBA
11/2002
1Carrier Proteins (Binding Protein)IBA
11/2002
1Transcription Factors (Transcription Factor)IBA
11/2002

Therapy/Procedure

6Drug Therapy (Chemotherapy)
05/2006 - 11/2002
3Premedication
07/2005 - 01/2004
2Adjuvant Chemotherapy
07/2005 - 08/2004
1Hysterotomy
12/2006
1Ovariectomy (Oophorectomy)
07/2005
1Pain Management
08/2004
1Drug Tapering
08/2004
1Combination Drug Therapy (Combination Chemotherapy)
08/2004
1Therapeutics
11/2002